Mechanisms and efficacy of vismodegib in the treatment of basal cell carcinoma

Discovery Medicine

Volumn 16, Issue 89, 2013, Pages 229-232

  Amin, Shivan H ^a   Motamedi, Kevin ^b   Ochsner, Matthew C ^b   Song, Tara E ^c   Hybarger, Charles P ^c  

^a DeKalb Medical Center   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c KAISER PERMANENTE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPAMINE; SARIDEGIB; VISMODEGIB;

ARTICLE; BASAL CELL CARCINOMA; BASAL CELL NEVUS SYNDROME; CANCER RECURRENCE; DISEASE COURSE; DISEASE DURATION; DRUG EFFICACY; FOLLOW UP; HUMAN; MULTICENTER STUDY (TOPIC); PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CLEARANCE; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

ANILIDES; CARCINOMA, BASAL CELL; CLINICAL TRIALS AS TOPIC; HUMANS; MALE; PYRIDINES;

EID: 84889602804     PISSN: 15396509     EISSN: 19447930     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Aasi S, Silkiss R, Tang JY, Wysong A, Liu A, Epstein E, Oro AE, Chang AL. New onset of keratoacanthomas after vismodegib treatment for locally advanced basal cell carcinomas: a report of 2 cases. JAMA Dermatol 149(2):242-243, 2013.
2. Amin S, Tibes R, Kim J, Hybarger C. Hedgehog antagonist GDC-0449 is effective in the treatment of advanced basal cell carcinoma. Laryngoscope 120(12):2456-2459, 2010.
3. Chang AL, Atwood SX, Tartar DM, Oro AE. Surgical excision after neoadjuvant therapy with vismodegib for a locally advanced basal cell carcinoma and resistant basal carcinomas in Gorlin syndrome. JAMA Dermatol 149(5):639-641, 2013.
4. Chang AL, Oro AE. Initial assessment of tumor regrowth after vismodegib in advanced basal cell carcinoma. Arch Dermatol 148(11):1324-1325, 2012.
5. Gailani MR, Ståhle-Bäckdahl M, Leffell DJ, Glynn M, Zaphiropoulos PG, Pressman C, Undén AB, Dean M, Brash DE, Bale AE, Toftgård R. The role of the human homologue of Drosophila patched in sporadic basal cell carcinoma. Nat Genet 14(1):78-81, 1996.
6. Goldberg LH, Landau JM, Moody MN, Kazakevich N, Holzer AM, Myers A. Resolution of odontogenic keratocysts of the jaw in basal cell nevus syndrome with GDC-0449. Arch Dermatol 147(7):839-841, 2011.
7. Graham RA, Chang I, Jin JY, Wang B, Dufek MB, Ayache JA, Ezzet F, Zerivitz K, Low JA, Dresser MJ. Daily dosing of vismodegib to steady state does not prolong the QTc interval in healthy volunteers. J Cardiovasc Pharmacol 61(1):83-89, 2013.
8. Graham RA, Hop CE, Borin MT, Lum BL, Colburn D, Chang I, Shin YG, Malhi V, Low JA, Dresser MJ. Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects. Br J Clin Pharmacol 74(5):788-796, 2012.
9. Graham RA, Lum BL, Cheeti S, Jin JY, Jorga K, Von HoffDD, Rudin CM, Reddy JC, Low JA, Lorusso PM. Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: The role of alpha-1-acid glycoprotein binding. Clin Cancer Res 17(8):2512-2520, 2011.
10. Hassounah NB, Bunch TA, McDermott KM. Molecular pathways: the role of primary cilia in cancer progression and therapeutics with a focus on Hedgehog signaling. Clin Cancer Res 18(9):2429-2435, 2012.
11. Jimeno A, Weiss GJ, Miller WH Jr, Gettinger S, Eigl BJ, Chang AL, Dunbar J, Devens S, Faia K, Skliris G, Kutok J, Lewis KD, Tibes R, Sharfman WH, Ross RW, Rudin CM. Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Clin Cancer Res 19(10):2766-2774, 2013.
12. Robarge KD, Brunton SA, Castanedo GM, Cui Y, Dina MS, Goldsmith R, Gould SE, Guichert O, Gunzner JL, Halladay J, Jia W, Khojasteh C, Koehler MF, Kotkow K, La H, Lalonde RL, Lau K, Lee L, Marshall D, Marsters JC Jr, et al. GDC-0449-a potent inhibitor of the hedgehog pathway. Bioorg Med Chem Lett 19(19):5576-5581, 2009.
13. Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang AL, Low JA, Mackey HM, Yauch RL, Graham RA, Reddy JC, Hauschild A. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 366(23):2171-2179, 2012.
14. Tang JY, Mackay-Wiggan JM, Aszterbaum M, Yauch RL, Lindgren J, Chang K, Coppola C, Chanana AM, Marji J, Bickers DR, Epstein EH Jr. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med 366(23):2180-2188, 2012.
15. U.S. FDA. FDA approves new treatment for most common type of skin cancer [News Release]. Jan. 30, 2012.
16. Von HoffDD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Mackey HM, Lum BL, Darbonne WC, Marsters JC Jr, de Sauvage FJ, Low JA. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 361(12):1164-1172, 2009.
17. Wolfe CM, Green WH, Cognetta AB Jr, Hatfield HK. Basal cell carcinoma rebound after cessation of vismodegib in a nevoid basal cell carcinoma syndrome patient. Dermatol Surg 38(11):1863-1866, 2012.